If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Aligner Dental Academy outlines how digital advancements are transforming the diagnosis and treatment of class II ...

Ormco Corporation, a leading provider of innovative orthodontic solutions for over 60 years, is excited to announce the ...

A research team from Helmholtz Munich, the Technical University of Munich (TUM) and the TUM University Hospital has developed ...

Yesafili, a vascular endothelial growth factor inhibitor, is used to treat several different types of ophthalmology ...

Traditional disease detection methods in agriculture often rely on manual observation by specialists, a process that is labor ...

A research team from Helmholtz Munich, the Technical University of Munich (TUM) and the TUM University Hospital has developed ...

Every step we take brings us closer to our vision of providing world-class healthcare." At The View Hospital, healthcare goes beyond medicine and technology – we are a family, above all.

PRFM is often the treatment of choice for those experiencing crepey undereye skin or fine lines due to collagen loss. "It's ...

The infusion pumps market is experiencing significant growth due to the increasing demand for advanced healthcare solutions, particularly in the management of chronic diseases and critical care.